Ocular Therapeutix Inc Surges After NDA Submission Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: 4
Ocular Therapeutix Inc shares rose by 26.55% after crossing above the 5-day SMA, reflecting strong investor interest following recent news.
The company plans to submit a New Drug Application for AXPAXLI for wet AMD in Q1 2026, contingent on positive data from the SOL-1 trial. This could position AXPAXLI as a leading treatment option in a competitive market.
With wet AMD affecting millions globally, the potential for AXPAXLI to improve patient adherence and outcomes is significant, suggesting a promising future for Ocular Therapeutix in the ophthalmology sector.
Analyst Views on OCUL
Wall Street analysts forecast OCUL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCUL is 23.43 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.280
Low
20.00
Averages
23.43
High
31.00
Current: 10.280
Low
20.00
Averages
23.43
High
31.00
About OCUL
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
